MA46278A - Molécules de liaison qui modulent une activité biologique exprimée par une cellule - Google Patents

Molécules de liaison qui modulent une activité biologique exprimée par une cellule

Info

Publication number
MA46278A
MA46278A MA046278A MA46278A MA46278A MA 46278 A MA46278 A MA 46278A MA 046278 A MA046278 A MA 046278A MA 46278 A MA46278 A MA 46278A MA 46278 A MA46278 A MA 46278A
Authority
MA
Morocco
Prior art keywords
cell
biological activity
binding molecules
activity expressed
modulate biological
Prior art date
Application number
MA046278A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Ton Logtenberg
Paulus Johannes Tacken
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA46278A publication Critical patent/MA46278A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046278A 2016-09-23 2017-09-22 Molécules de liaison qui modulent une activité biologique exprimée par une cellule MA46278A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16190499 2016-09-23

Publications (1)

Publication Number Publication Date
MA46278A true MA46278A (fr) 2019-07-31

Family

ID=57132987

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046278A MA46278A (fr) 2016-09-23 2017-09-22 Molécules de liaison qui modulent une activité biologique exprimée par une cellule

Country Status (19)

Country Link
US (2) US11685786B2 (fr)
EP (2) EP3515951B1 (fr)
JP (3) JP7305538B2 (fr)
KR (2) KR20250007013A (fr)
CN (2) CN109983033B (fr)
AU (3) AU2017332452B2 (fr)
BR (1) BR112019005895A2 (fr)
CA (1) CA3038020A1 (fr)
EA (1) EA201990578A1 (fr)
ES (1) ES2981272T3 (fr)
IL (2) IL265541B2 (fr)
MA (1) MA46278A (fr)
MX (1) MX2019003241A (fr)
NZ (1) NZ751956A (fr)
PH (1) PH12019550044A1 (fr)
TW (1) TWI879715B (fr)
UA (1) UA127449C2 (fr)
WO (1) WO2018056821A1 (fr)
ZA (1) ZA201902146B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
EP3858858A1 (fr) 2016-06-20 2021-08-04 F-Star Delta Limited Molécules de liaison liant pd-l1 et lag-3
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
UA128304C2 (uk) 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
CA3095595A1 (fr) * 2018-03-30 2019-10-03 Eureka Therapeutics, Inc. Constructions ciblant cd22 et leurs utilisations
US11993655B2 (en) 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
CN112351998B (zh) * 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
PL3820569T3 (pl) * 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (fr) * 2018-10-09 2020-04-15 Numab Therapeutics AG Anticorps dirigés contre cd137 et leurs procédés d'utilisation
AU2019375014A1 (en) * 2018-11-06 2021-05-27 Genmab A/S Antibody formulation
WO2020231809A1 (fr) * 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd137 humanisés et leurs utilisations
US11725058B2 (en) * 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
CN114555638B (zh) * 2019-10-11 2023-08-22 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
US20230087164A1 (en) * 2020-02-04 2023-03-23 Genmab A/S Antibodies for use in therapy
JP7745556B2 (ja) * 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
KR20220164548A (ko) 2020-04-03 2022-12-13 소렌토 쎄라퓨틱스, 인코포레이티드 Lag3에 결합하는 조작된 항체
CN115698067A (zh) * 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
WO2021222074A1 (fr) * 2020-04-28 2021-11-04 Ohio University Procédés pour prolonger la durée de conservation de sang et/ou de globules rouges donnés stockés et compositions de globules rouges traités ainsi produites
KR20230013030A (ko) 2020-05-21 2023-01-26 메뤼스 엔.페. Ig-유사 분자의 생산을 위한 방법 및 수단
CN116194124A (zh) * 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
CN113416249B (zh) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
US20240052050A1 (en) * 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
MX2023008172A (es) * 2021-01-08 2023-07-18 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
PH12023552704A1 (en) 2021-03-31 2024-02-19 Merus Nv Novel multispecific antibodies
EP4469476A1 (fr) 2022-01-25 2024-12-04 Merus N.V. Polythérapie pour le traitement du cancer
CN119546644A (zh) * 2022-05-18 2025-02-28 瑞泽恩制药公司 结合cd38和4-1bb的多特异性抗原结合分子及其用途
WO2025012620A1 (fr) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Constructions de liaison

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
AU2001236621B2 (en) * 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
EP2314629B2 (fr) 2002-07-18 2022-11-16 Merus N.V. Production recombinante de mélanges d'anticorps
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2008531557A (ja) * 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
KR20130087517A (ko) 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
CA2899577C (fr) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Polytherapie pour induire une reponse immunitaire a une maladie
WO2015063339A1 (fr) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production de cellules t reciblant des immunoglobulines héréro-dimériques
WO2015095423A2 (fr) * 2013-12-17 2015-06-25 Genentech, Inc. Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
KR102568808B1 (ko) * 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
LT3623386T (lt) 2015-01-08 2022-08-10 BioNTech SE Agonistiniai tnf receptorius surišantys agentai
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
CA2973720A1 (fr) 2015-01-14 2016-07-21 Compass Therapeutics Llc Constructions de liaison a des antigenes immunomodulateurs multispecifiques
EP3268037B1 (fr) * 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Agonistes cd27
HK1249532A1 (zh) 2015-04-07 2018-11-02 F. Hoffmann-La Roche Ag 具有激动剂活性的抗原结合复合体及使用方法
AU2016265447B2 (en) * 2015-05-21 2022-06-16 Alligator Bioscience Ab Novel polypeptides
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
EP3313876B1 (fr) 2015-06-23 2025-01-22 Innate Pharma Proteines multispecifiques liant des antigenes
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
KR20180054877A (ko) 2015-10-07 2018-05-24 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
IL298686A (en) * 2016-01-11 2023-01-01 Inhibrx Inc Multivalent and multispecific ox40-binding fusion proteins
WO2017182672A1 (fr) 2016-04-22 2017-10-26 Alligator Bioscience Ab Nouveaux polypeptides bispécifiques dirigés contre le cd137
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
KR20190014525A (ko) * 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
WO2018045110A1 (fr) 2016-08-30 2018-03-08 Xencor, Inc. Anticorps immunomodulateurs bispécifiques qui se lient à des récepteurs de costimulation et de points de contrôle
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
JP2019537429A (ja) 2019-12-26
AU2024220074A1 (en) 2024-10-17
ZA201902146B (en) 2024-08-28
BR112019005895A2 (pt) 2019-06-11
ES2981272T3 (es) 2024-10-08
JP2025139596A (ja) 2025-09-26
JP2023116811A (ja) 2023-08-22
EA201990578A1 (ru) 2019-10-31
CN109983033B (zh) 2023-10-31
JP7305538B2 (ja) 2023-07-10
IL311603B2 (en) 2026-02-01
US20240209105A1 (en) 2024-06-27
KR20250007013A (ko) 2025-01-13
NZ751956A (en) 2022-01-28
IL265541A (en) 2019-05-30
TW201920653A (zh) 2019-06-01
AU2021202085B2 (en) 2024-07-11
TWI879715B (zh) 2025-04-11
US20200017595A1 (en) 2020-01-16
WO2018056821A8 (fr) 2019-05-02
EP4342912A2 (fr) 2024-03-27
EP3515951A1 (fr) 2019-07-31
IL265541B1 (en) 2024-04-01
IL265541B2 (en) 2024-08-01
AU2017332452A1 (en) 2019-04-11
PH12019550044A1 (en) 2019-11-11
EP3515951B1 (fr) 2024-02-28
AU2021202085A1 (en) 2021-04-29
CN117510643A (zh) 2024-02-06
CN109983033A (zh) 2019-07-05
UA127449C2 (uk) 2023-08-30
KR20190065318A (ko) 2019-06-11
CA3038020A1 (fr) 2018-03-29
AU2017332452B2 (en) 2021-01-07
EP4342912A3 (fr) 2024-05-22
MX2019003241A (es) 2019-11-12
US11685786B2 (en) 2023-06-27
IL311603B1 (en) 2025-10-01
WO2018056821A1 (fr) 2018-03-29
IL311603A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL271817A (en) Binding molecules that modulate a biological activity expressed by a cell
IL265541A (en) Binding molecules that regulate biological activity expressed by a cell
IL270514B (en) Agricultural compositions
IL271833A (en) Antibodies that regulate biological activity expressed by a cell
EP3861130A4 (fr) Modulateurs génétiques modifiés
PL3880654T3 (pl) Związki 2-formylo-3-hydroksyfenyloksymetylowe zdolne do modulowania hemoglobiny
EP3542215A4 (fr) Réseaux de diffraction à cristaux liquides spatialement variables
EP3619310A4 (fr) Polynucléotides modulateurs
ECSP18030970A (es) Proteínas de unión a pd-1 y métodos para usarlas
EP3568416A4 (fr) Récepteurs antigéniques chimériques ciblant tim-1
EP3352829A4 (fr) Ensemble coudé
EP3861844C0 (fr) Analyse de données agricoles
MA54760A (fr) Molécules de liaison qui inhibent la croissance d'un cancer
IL258359A (en) Farnesoid x receptor modulators
DK3292137T3 (da) Proteiner specifikke for cd137
EP3719036A4 (fr) Molécule de liaison à un ligand ayant une activité de liaison à un ligand réglable
MA53887A (fr) Anticorps à liaison protofibrille a-bêta améliorée
IL269100A (en) Stabilized protein-bound cannabinoid compositions
IL272361A (en) Antibody binding active alpha-synuclein
EP3349814A4 (fr) Matrice extracellulaire soluble non gélifiante présentant une activité biologique
EP3717652A4 (fr) Thérapie génique pour mucopolysaccharidose de type iiib
SI3200822T1 (sl) Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
EP3250230A4 (fr) Modulateurs d'activité du complément
EP3728206A4 (fr) Composés ciblant l'acide nucléique dirigés sur la matrice
EP3619311C0 (fr) Assemblage d'adn